Dubbing stress “today’s public enemy number-one,” Lipogen (Haifa, Israel) is now strengthening its campaign to gear its recently launched Lipogen PSPA ingredient to the stress-management dietary supplement market.
Lipogen PSPA is a combination of phosphatidylserine (PS) and phosphatidic acid (PA). Two human clinical trials attest to Lipogen PSPA’s benefits to brain health and stress management.
The first study1, published in the journal Stress in 2004, was the first to confirm a “pronounced dampening effect" of Lipogen’s PS+PA daily on "the reactivity of the pituitary–adrenal axis to stress” in 80 subjects.
The second study2, published in Lipids in Health and Disease in 2014, again found that the PS+PA combo lowered stress, leading the researchers to conclude that “in chronically stressed subjects, PAS 400 [featuring 400 mg PS and 400 mg PA] can be expected to buffer a hyper-responsivity of the [hypothalamus-pituitary-adrenal-axis] to acute stressors by normalizing cortisol responses.”
This year, Lipogen PSPA made its first U.S. debut in a stress-management supplement from Jarrow Formulas. “In launching the PS-PA Synergy [product], we’re presenting a new dietary supplement based on phospholipids to proactively support stress management at work and for students,” said Jarrow Formulas president and founder Jarrow Rogovin, in a press release.
Lipogen says it holds patents in the Untied States, the EU, and Canada to pave the way for its marketing partners.
- Hellhammer J et al., “Effects of soy lecithin phosphatidic acid and phosphatidylserine complex (PAS) on the endocrine and psychological responses to mental stress,” Stress, vol. 7, no. 2 (June 2004): 119-126
- Hellhammer J et al., “A soy-based phosphatidylserine/phosphatidic acid complex (PAS) normalizes the stress reactivity of hypothalamus-pituitary-adrenal-axis in chronically stressed male subjects: a randomized, placebo-controlled study,” Lipids in Health and Disease. Published online July 31, 2014.